The upstream and downstream industry chain combing of the medical beauty track is very comprehensive and worth collecting!
Medical beauty, as an extension of the consumer demand for beauty, synthesizes the medical and consumer attributes, is a high-quality track with both a high threshold for medical treatment and a high ceiling for consumption, which is an investment track worth paying attention to in 2022.
White wine for men, medical beauty for women. We will find that more and more women are willing and able to invest in beauty. Of course, the medical beauty industry chain is relatively long, on the whole, the upstream raw materials and midstream pharmaceutical equipment link moat barriers deeper, is the value of the medical beauty industry chain in the more centralized links, the main test of the enterprise's R & D strength, differentiated product pipeline layout and market cultivation capabilities; downstream service link overall competition pattern is more dispersed, there is a larger space for integration in the future.
The following combing industry chain related stocks:
First, the upstream, raw materials
Huaxi Biological: The largest hyaluronic acid in the world. raw materials, hyaluronic acid raw materials in 2020 to contribute 26% of gross profit.
Lushang Development: pharmaceutical-grade hyaluronic acid is applying for registration, 2020 cosmetic food-grade hyaluronic acid to achieve net profit of 24.61 million yuan of attribution, accounting for 4% of the annual attribution.
Second, midstream, with hyaluronic acid injections, botulinum toxin as a representative product of various manufacturers
Aimer: hyaluronic acid products as the main focus, 2020 medical beauty products contribute to gross profit of more than 99% .
Haohai Shengke: with hyaluronic acid products as the main focus, medical aesthetic products will contribute 21% of gross profit in 2020 .
East China Pharmaceutical: a wide range of medical aesthetic products, medical aesthetic products are expected to contribute 6~8% of net profit in 2021 .
Bethenny: the subsidiary Kunming Winona is mainly engaged in medical aesthetic services, including laser, micro-needling and other beauty services.
Jingfeng Pharmaceuticals: the company is building a series of pharmaceutical hyaluronic acid products.
Changshan Pharmaceuticals: Subsidiary Hebei Changshan Kelonite Biotechnology Co.
Xinhua Jin: subsidiary Qingdao Libaijian is involved in the field of plastic surgery.
Guanhao Bio: the company's product breast patch can be used in cosmetic surgery, breast augmentation surgery assistance.
Shuanglu Pharmaceuticals: 34% participation in the background of Montblanc Bio's main product is hyaluronic acid.
Third, downstream, operating hospitals, clinics departments and other medical aesthetic institutions business companies
Lanzi shares: 2020 medical aesthetic business can contribute to about 28% of the revenue, is expected to contribute to about 50% of net profit .
Blonde Gold Rabbit: the acquisition of medical beauty hospital Hanfei Investment, 2021 net profit commitment of not less than 50 million yuan, taking into account 36% equity share, equivalent to 39% of the company's net profit in 2019 . Hanfei Investment holds five medical beauty organizations with more than 1,000 employees .
Aoyuan Meigu: Acquisition of 55% of the equity of the medical beauty organization Zhejiang Liantianmei, Liantianmei two-year commitment to the cumulative net profit of not less than $157 million, the company's two-year net profit consensus expectations of 123 , 220 million yuan, cumulative about 45% of the company's net profit .
Suning Global: the next 2~3 years is expected to medical beauty net profit of 50 million +, the current four organizations have not been consolidated. The company's 2022 net profit of 1.5 billion yuan of net income from the mother of consensus expectations, or 3.3% .
Guangpu shares: the acquisition of the military beauty hospital (51% stake) is approved by the Chongqing Municipal Health Bureau of the first level of plastic surgery and cosmetic specialty hospital .
The company's official website shows that the clinic has advanced high-end medical beauty equipment.
Yuexin Health : The wholly-owned Shanghai Yuexin Outpatient Comprehensive Department, which is approved by the Shanghai Municipal Health Commission, has the qualification to carry out first- and second-degree cosmetic surgery.
Huabang Health: Its Mane Dermatology & Cosmetic Hospital has a chain of more than 30 organizations nationwide.
Aoyang Health : Holding Zhangjiagang Wei-En Medical Beauty Hospital, a subsidiary 12.75 million in 2018 to acquire a 51% stake .
Jiemin Pharmaceuticals: the company's Boao International Hospital Medical Beauty Center has opened in 2020 .
Jinling Pharmaceutical: the business scope of the company's Anqing Petrochemical Hospital includes medical aesthetics department .
Yingkang Life: its Sichuan Friendship Hospital has a specialty department of plastic surgery and aesthetics.
CK Health : Zhengzhou Dongfang Women's Hospital contains medical aesthetics department and carries out skin care related services.
Innovative Healthcare: Subsidiary Jiafeng Clinic is mainly engaged in medical aesthetics and gynecology and cervix.
Pingtan Development: the company's fund-raising project Pingtan Strait Medical Park construction project, including beauty hospital.
International Medicine: the company's Xi'an International Medicine Hi-Tech Hospital under the medical aesthetic department .
Finally, remind everyone to pay attention to:
No matter how good the company, how great the logic, is the need to consider a good point of purchase; no good point of purchase, and then good company, and even more great logic, then also will lose money! Without a good buy point, everything is a floating cloud! Remember to remember!